SCHEMBL5875575

SCHEMBL5875575

Nc1nc(-c2ccccc2)c(C(=O)N2CCCCC2)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
MAPT P10636 3/20 0.55
KDM4E B2RXH2 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
TLR9 Q9NR96 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HPGD P15428 5/20 0.53
HSD17B10 Q99714 2/20 0.53
HTT P42858 2/20 0.53
MAPK1 P28482 2/20 0.53
ALOX15 P16050 1/20 0.53
CNR1 P21554 1/20 0.51
ALOX5 P09917 1/20 0.50
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
PTGS2 P35354 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30218357 0.87 CNR1 (0.59) ALDH1A1KDM4ENPC1RAB9AHPGD
SCHEMBL6195636 0.84 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL1381524 0.79 POLB (0.52) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL1382338 0.78 USP2 (0.48) ALDH1A1MAPTHSD17B10MAPK1POLB
SCHEMBL27653923 0.78 ALDH1A1 (0.64) ALDH1A1MAPTKDM4EHSD17B10HTT
SCHEMBL2762916 0.78 ALDH1A1 (0.64) ALDH1A1MAPTKDM4EHSD17B10HTT
SCHEMBL1383740 0.77 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL2521905 0.76 ALDH1A1 (0.62) ALDH1A1MAPTKDM4ENPC1RAB9A
Hydrochloric Acid SCHEMBL27583076 0.76 ALDH1A1 (0.62) ALDH1A1MAPTKDM4ENPC1RAB9A
SCHEMBL25351654 0.76 KMT2A (0.58) ALDH1A1MAPTKDM4EL3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP ALDH1A1 590/4885MAPT 9/4885KDM4E 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.